Moderna vaccine 94.5% effective in second breakthrough
In this file photo a view of Moderna headquarters is seen on May 8, 2020 in Cambridge, Massachusetts. US biotech firm Moderna on May 18, 2020 reported "positive interim" results in the first clinical tests of its vaccine against the new coronavirus performed on a small number of volunteers. The vaccine appeared to produce an immune response in eight people who received it, of the same amplitude as that observed in people infected with the virus, the company said, adding that phase 3 trials with a large number of volunteers would begin in July.
AFP/MADDIE MEYER/GETTY IMAGES NORTH AMERICA

Moderna vaccine 94.5% effective in second breakthrough

Issam Ahmed (Agence France-Presse) - November 16, 2020 - 9:06pm

WASHINGTON, United States — US biotech firm Moderna on Monday announced its experimental vaccine against COVID-19 was 94.5% effective, marking a second major breakthrough in the vaccine hunt.

Moderna released early results from a clinical trial with more than 30,000 participants, after US pharmaceutical company Pfizer and its German partner BioNTech last week said their vaccine was 90% effective. 

Both vaccine frontrunners are based on a new platform called messenger RNA, which is faster to produce than traditional vaccines and effectively turn human cells into vaccine factories.

"This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease," said Stephane Bancel, Moderna's CEO.

The company plans to submit applications for emergency approval in the US and around the world within weeks, and says it expects to have approximately 20 million doses ready to ship in the US by the end of the year.

Global infections from COVID-19 have soared past 54 million with more than 1.3 million deaths since the virus emerged in China late last year.

The Moderna vaccine, which was co-developed by the US National Institutes of Health, is given in two doses 28 days apart, and the preliminary results are based on 95 volunteers of the 30,000 who fell ill with COVID-19.

Of the 95, 90 had been in the trial's placebo group, and five in the group that received the drug, called mRNA-1273.

'Tremendously exciting'

There were 11 people who fell severely ill, all of whom were in the placebo group.

The vaccine was well tolerated, with the majority of side-effects classed as mild or moderate.

After the first dose, about three percent of people had injection site pain classed as severe. 

Among side-effects classed as severe after the second dose, about 10 percent had fatigue, nine percent had muscle pain, five percent had joint pain or headaches, four percent had other pain and two percent had redness at the injection site.

These adverse events were "short lived," according to a statement.

"This news from Moderna is tremendously exciting and considerably boosts optimism that we will have a choice of good vaccines in the next few months," said Peter Openshaw, a professor of experimental medicine at Imperial College London.

Crucially, Moderna also announced that its vaccine can remain stable at standard refrigerator temperatures of 2 degrees Celsius to 8 degrees Celsius (36 degrees Fahrenheit to 46 degrees Fahrenheit) for 30 days.

The company added it could be kept in long-term storage at standard freezer temperatures of -20 degrees Celsius (-4 degrees Fahrenheit) for up to six months.

Pfizer's vaccine, on the other hand, needs to be stored in deep-freezer conditions which could complicate supply chain logistics, particularly in less developed countries.

It is not yet clear how long lasting the protection will be from either the Moderna or Pfizer vaccines, nor how well they work for the elderly, the age-group at highest risk from COVID-19.

COVID-19 VACCINES MODERNA NOVEL CORONAVIRUS
As It Happens
LATEST UPDATE: January 14, 2021 - 7:41pm

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

January 14, 2021 - 7:41pm

Both Pope Francis and his predecessor, former pope Benedict XVI, have received the coronavirus vaccine, the Vatican says on Thursday.

"I can confirm that as part of the Vatican City State vaccination programme to date, the first dose of the Covid-19 vaccine has been administered to Pope Francis and the Pope Emeritus," spokesman Matteo Bruni says. — AFP

January 13, 2021 - 1:25pm

President Joko Widodo receives the first COVID-19 vaccine in Indonesia.  The shot, from China's Sinovac, kicks off the massive immunization campaign in the country dealing with one of most number of cases in the region.

Indonesia opted to secure millions of doses from the Chinese pharmaceutical company whose lack of transparency about its vaccine sparks concerns. While the Philippines ordered 25 million doses, Indonesia secured 125.5 million from Sinovac.

Indonesia is also expecting 50 million doses from Astrazeneca, 150 million from American biotech firm Novovax, 60 million from Sinopharm and 20 million from CanSino, making it the third territory in the world with the most number of confirmed doses after Europe and the United States. (Handout photo)

January 13, 2021 - 7:17am

The Chinese-developed Coronavac COVID-19 vaccine has demonstrated a 50 percent efficacy following tests in Brazil, the organization in charge of its production in the South American country says.

Coronavac has been given to frontline health care workers in close contact with coronavirus patients.

The Butantan Institute repeated its claim from last week that the vaccine is 78% effective in preventing mild cases that needed treatment and showed 100% efficacy in staving off moderate to serious cases. — AFP

January 12, 2021 - 9:03pm

Switzerland gives the green light Tuesday to the Moderna vaccine against the new coronavirus — the second jab it has authorised for use, joining the vaccine produced by Pfizer-BioNTech.

The Swissmedic regulatory authority said the vaccine from US firm Moderna had shown a "high efficacy rate", and could be deployed immediately.

The neighbouring European Union gave its approval to the Moderna vaccine last Wednesday, with Britain doing likewise on Friday. —  AFP

January 12, 2021 - 5:28pm

AstraZeneca and Oxford University have applied for authorisation for their coronavirus vaccine in the EU with a decision possible by January 29, the European Medicines Agency says on Tuesday.

The jab would be the third available for the 27-nation European Union after the Pfizer-BioNTech and Moderna drugs, as the bloc struggles to speed up the rollout.

"EMA has received an application for conditional marketing authorisation for a COVID-19 vaccine developed by AstraZeneca and Oxford University," the Amsterdam-based regulator says in a statement. —  AFP

Philstar
  • Latest
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with